Linatab M ER 5 mg + 1000 mg is an extended-release oral combination therapy for adults with type 2 diabetes mellitus, designed to provide effective and sustained glycemic control. This formulation combines Linagliptin, a DPP-4 inhibitor, with Metformin Hydrochloride (extended-release), allowing for once-daily dosing while minimizing gastrointestinal side effects. It is suitable for patients who require enhanced blood glucose management beyond lifestyle modifications.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Linagliptin: Dipeptidyl Peptidase-4 (DPP-4) inhibitor

• Metformin Hydrochloride (ER): Biguanide antidiabetic agent

Pharmacology

The combination of Linagliptin and Metformin ER addresses hyperglycemia via dual mechanisms:

1. Linagliptin (5 mg): Inhibits the DPP-4 enzyme, increasing incretin hormone levels (GLP-1 and GIP), which:

   • Stimulate glucose-dependent insulin secretion from pancreatic beta cells

   • Suppress glucagon secretion from pancreatic alpha cells

2. Metformin ER (1000 mg): Slowly releases Metformin to reduce hepatic glucose production and improve insulin sensitivity in peripheral tissues over a prolonged period.

Together, these mechanisms control both fasting and postprandial glucose levels effectively, improving overall glycemic management.

Indications

Linatab M ER is indicated for:

• Adults with type 2 diabetes mellitus inadequately controlled by diet and exercise

• Patients who require dual therapy with Linagliptin and Metformin

• Individuals who cannot achieve sufficient glycemic control with Metformin alone or other oral antidiabetic agents

Dosage and Administration

• Adults: Take **one tablet once daily with the evening meal.

• Renal Impairment: Linagliptin does not require dose adjustment; Metformin ER must be used cautiously in patients with reduced renal function.

• Combination Therapy: Linatab M ER can be combined with other antidiabetic agents under medical supervision.

Contraindications

• Hypersensitivity to Linagliptin, Metformin, or any excipients

• Severe renal impairment, acute or chronic metabolic acidosis, diabetic ketoacidosis

• Conditions predisposing to lactic acidosis

Side Effects

Linatab M ER is generally well tolerated. Possible side effects include:

• Gastrointestinal disturbances: nausea, vomiting, diarrhea, abdominal discomfort (less common due to ER formulation)

• Hypoglycemia when combined with insulin or sulfonylureas

• Rarely: pancreatitis or lactic acidosis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Regular renal and hepatic function monitoring is recommended

• Maintain adequate hydration during Metformin therapy

• Temporarily discontinue Metformin before radiologic contrast procedures

• Use with caution in patients with a history of hypersensitivity or pancreatitis

Drug Interactions

• Linagliptin has minimal CYP-mediated interactions, but caution is advised with strong CYP3A4 inducers or inhibitors

• Metformin ER may interact with cimetidine, diuretics, or contrast agents, affecting renal clearance

Pregnancy and Lactation

• Pregnancy: Category B for Linagliptin; use Metformin ER under medical supervision only if necessary

• Lactation: Safety not established; caution advised

Storage Conditions

Store in a cool, dry place below 30°C, away from light and moisture. Keep out of reach of children.

Mode of Action

• Linagliptin: Enhances incretin hormone activity, stimulating insulin release and suppressing glucagon in a glucose-dependent manner

• Metformin ER: Reduces hepatic glucose output and enhances peripheral glucose uptake gradually over 24 hours

This combination provides sustained blood glucose control, improving compliance and minimizing side effects associated with immediate-release formulations.